Vestal Point Capital LP Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 73.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,000,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 1,700,000 shares during the quarter. KalVista Pharmaceuticals comprises approximately 3.5% of Vestal Point Capital LP's portfolio, making the stock its 7th largest holding. Vestal Point Capital LP owned approximately 9.25% of KalVista Pharmaceuticals worth $46,320,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in KalVista Pharmaceuticals by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company's stock worth $263,000 after acquiring an additional 944 shares in the last quarter. ClariVest Asset Management LLC grew its holdings in KalVista Pharmaceuticals by 2.8% during the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company's stock worth $673,000 after acquiring an additional 1,535 shares during the period. Nicholas Investment Partners LP increased its holdings in KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company's stock valued at $2,172,000 after buying an additional 1,714 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth about $25,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company's stock worth $182,000 after purchasing an additional 3,314 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 8,077 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares of the company's stock, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company's stock, valued at $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,016 shares of company stock worth $319,344. 10.50% of the stock is owned by insiders.

KalVista Pharmaceuticals Stock Down 0.3 %

KalVista Pharmaceuticals stock traded down $0.03 during mid-day trading on Friday, hitting $10.06. 302,300 shares of the company's stock traded hands, compared to its average volume of 482,509. The company has a market cap of $434.79 million, a PE ratio of -2.86 and a beta of 0.92. The firm has a 50 day moving average price of $10.96 and a 200 day moving average price of $11.92. KalVista Pharmaceuticals, Inc. has a one year low of $7.39 and a one year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on KALV. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).